|Articles|September 1, 2001

Psychiatric Times Vol 18 No 9
Volume 18
Issue 9

Role Model

Role Model - Poetry of the Times

Back then, doctors drove black Cadillacs
and kept office hours at home.

Articles in this issue

about 20 years ago

Article

Treating Tobacco Dependence in Patients With Psychiatric Comorbidities

almost 25 years ago

Article

Teaching Children With Disabilities How To Succeed

almost 25 years ago

Article

Congressman Gephardt Gives Historic Talk On the Future of Mental Health Care

almost 25 years ago

Article

New Developments in Treating Anxiety Disorders

almost 25 years ago

Article

Facilitating Mourning Following Parental Death

almost 25 years ago

Article

Ensuring Appropiate Treatment for Patients

almost 25 years ago

Article

Coping When Mother Kills Father

almost 25 years ago

Article

An Early Warning Sign for Violence

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

AD04 Application Submitted to FDA Commissioner’s National Priority Voucher Pilot Program for Potential Expedited Review

ByLeah Kuntz

April 27th 2026

AD04 for Alcohol Use Disorder: Favorable Feedback From FDA Following End of Phase 2 Meeting

ByLeah Kuntz

September 16th 2025

FDA Grants Fast Track Designation to Pemvidutide for Treatment of Alcohol Use Disorder

ByLeah Kuntz

August 19th 2025

End of Phase 2 Meeting With the FDA: Adial Prepares to Advance AD04 for Alcohol Use Disorder

ByLeah Kuntz

August 6th 2025

Differences in Experiences Must Influence Interventions

BySara Luciano

July 14th 2025

Latest CME

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Role Model

Articles in this issue

Related Content

AD04 Application Submitted to FDA Commissioner’s National Priority Voucher Pilot Program for Potential Expedited Review

AD04 for Alcohol Use Disorder: Favorable Feedback From FDA Following End of Phase 2 Meeting

FDA Grants Fast Track Designation to Pemvidutide for Treatment of Alcohol Use Disorder

End of Phase 2 Meeting With the FDA: Adial Prepares to Advance AD04 for Alcohol Use Disorder

Differences in Experiences Must Influence Interventions

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

Remlifanserin for the Treatment of Alzheimer Disease Psychosis Receives FDA Fast Track Designation

Future DSM Plans Overlook Core Problem of Validity

Targeting APOE4: A Promising Therapeutic Strategy for Alzheimer Disease

Classic Drug, New Target: Lithium as Disease-Modifying in Alzheimer Dementia

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy